New York, NY / ACCESSWIRE / August 20, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman’s Blog, written by the Company’s Chairman and CEO, Mr. Nevan Elam. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Following the recent announcement of MannKind and Sanofi’s licensing agreement to bring Afrezza to market, Mr. Elam reflects on what the news means for AntriaBio and the industry as a whole. He writes, "I think the announcement of this partnership bodes extremely well for AntriaBio as it highlights a renewed focus on novel insulin therapies that reduce the injection burden for patients." Read why Mr. Elam believes big pharma is "looking outside its four walls" in his full blog post on TheChairmansBlog.com (http://www.thechairmansblog.com/antriabio/nevan-elam/big-pharma-strategic-partnerships/).
About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes. For more information visit: www.antriabio.com.
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com
SOURCE: The Chairmans Blog